{"sourcedb":"DevicePMAs@therightstef","sourceid":"P940016_S013","text":"Approval for design modifications to the plasmat secura system including the use of the plasmat futura machine with software version 2.6.01, the futura kit, and individually packaged components.  The device, as modified, will be marketed under the trade name h. e. l. p. plasmat futura apheresis system and is indicated for acutely removing low-density lipoprotein cholesterol (ldl-c) from the plasma of the following high-risk patient populations for whom diet has been ineffective and maximum drug therapy has either been ineffective or not tolerated: group a: functional hypocholesterol-emic homozygotes with ldl-c \u003E 500 mg/dl; group b: functional hypocholesterol-emic homozygotes with ldl-c \u003E 300 mg/dl; and group c: functional hypocholesterol-emic homozygotes with ldl-c \u003E 200 mg/dl and documented coronary artery disease.","project":"consensus_PMA_Age_Indications"}